Logo image of PSTI

PLURISTEM THERAPEUTICS INC (PSTI) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PSTI - US72940R3003 - Common Stock

1 USD
-0.03 (-2.91%)
Last: 7/25/2022, 8:17:24 PM
1.03 USD
+0.03 (+3%)
After Hours: 7/25/2022, 8:17:24 PM
Fundamental Rating

2

Overall PSTI gets a fundamental rating of 2 out of 10. We evaluated PSTI against 530 industry peers in the Biotechnology industry. While PSTI seems to be doing ok healthwise, there are quite some concerns on its profitability. PSTI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PSTI has reported negative net income.
PSTI Yearly Net Income VS EBIT VS OCF VS FCFPSTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 0 20M -20M 40M

1.2 Ratios

Industry RankSector Rank
ROA 59.22%
ROE 123.02%
ROIC 52.39%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PSTI Yearly ROA, ROE, ROICPSTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 50 -50 -100 -150

1.3 Margins

Industry RankSector Rank
OM -20665.22%
PM (TTM) 20373.91%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PSTI Yearly Profit, Operating, Gross MarginsPSTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 -50K -100K

More info and screens

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so PSTI is creating value.
PSTI has more shares outstanding than it did 1 year ago.
PSTI has a worse debt/assets ratio than last year.
PSTI Yearly Shares OutstandingPSTI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M
PSTI Yearly Total Debt VS Total AssetsPSTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

2.2 Solvency

An Altman-Z score of 9.66 indicates that PSTI is not in any danger for bankruptcy at the moment.
A Debt/Equity ratio of 0.60 indicates that PSTI is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Altman-Z 9.66
ROIC/WACC5.53
WACC9.48%
PSTI Yearly LT Debt VS Equity VS FCFPSTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 8.22 indicates that PSTI has no problem at all paying its short term obligations.
PSTI has a Quick Ratio of 8.22. This indicates that PSTI is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 8.22
Quick Ratio 8.22
PSTI Yearly Current Assets VS Current LiabilitesPSTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

PSTI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.26%, which is quite good.
Looking at the last year, PSTI shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)9.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.42%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PSTI will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.41% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y40.89%
EPS Next 2Y2.16%
EPS Next 3Y25.38%
EPS Next 5Y14.41%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PSTI Yearly Revenue VS EstimatesPSTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2018 2019 2020 2023 2024 2025 2026 50M 100M 150M
PSTI Yearly EPS VS EstimatesPSTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PSTI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PSTI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PSTI Price Earnings VS Forward Price EarningsPSTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.14
PSTI Per share dataPSTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as PSTI's earnings are expected to grow with 25.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.16%
EPS Next 3Y25.38%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PSTI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PLURISTEM THERAPEUTICS INC

NASDAQ:PSTI (7/25/2022, 8:17:24 PM)

After market: 1.03 +0.03 (+3%)

1

-0.03 (-2.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2022-05-09/amc
Earnings (Next)N/A N/A
Inst Owners0.52%
Inst Owner Change-0.36%
Ins Owners15.65%
Ins Owner Change0%
Market Cap32.35M
Revenue(TTM)230.00K
Net Income(TTM)46.86M
Analysts82.5
Price Target3.57 (257%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 140.64
P/FCF N/A
P/OCF N/A
P/B 0.85
P/tB N/A
EV/EBITDA -0.14
EPS(TTM)-1.47
EYN/A
EPS(NY)-1.68
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.01
BVpS1.18
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 59.22%
ROE 123.02%
ROCE N/A
ROIC 52.39%
ROICexc N/A
ROICexgc 52.39%
OM -20665.22%
PM (TTM) 20373.91%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.22
Quick Ratio 8.22
Altman-Z 9.66
F-Score6
WACC9.48%
ROIC/WACC5.53
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.42%
EPS Next Y40.89%
EPS Next 2Y2.16%
EPS Next 3Y25.38%
EPS Next 5Y14.41%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

PLURISTEM THERAPEUTICS INC / PSTI FAQ

What is the ChartMill fundamental rating of PLURISTEM THERAPEUTICS INC (PSTI) stock?

ChartMill assigns a fundamental rating of 5 / 10 to PSTI.


What is the valuation status of PLURISTEM THERAPEUTICS INC (PSTI) stock?

ChartMill assigns a valuation rating of 2 / 10 to PLURISTEM THERAPEUTICS INC (PSTI). This can be considered as Overvalued.


How profitable is PLURISTEM THERAPEUTICS INC (PSTI) stock?

PLURISTEM THERAPEUTICS INC (PSTI) has a profitability rating of 8 / 10.